Phyllodes Tumor of the Breast during Pregnancy and Lactation; A Systematic Review

Sadaf Alipour, MD1,2; Amirhossein Eskandari, MD3; Fatimah Mat Johar, MD4,5; Shinji Furuya, MD6

1Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
2Department of Surgery, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
3Deputy of Education, Ministry of Health, Tehran, Iran
4Reconstructive Sciences Unit, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kota Bharu, Kelantan, Malaysia
5Hospital Universiti Sains Malaysia, Jalan Raja Perempuan Zainab II, Kubang Kerian, Kota Bharu, Kelantan, Malaysia
6First Department of Surgery, Faculty of Medicine, University of Yamanashi, Shimokato, Chuo, Yamanashi, Japan

Abstract
Background: Phyllodes tumor (PT) is a rare tumor of the breast, which may occur during pregnancy or lactation. Several studies have reviewed and discussed PT occurring in pregnancy, gathering up to 14 patients. We performed a thorough systematic review of the literature in an attempt to find all reported cases, and identify their common characteristics.

Methods: We searched Google scholar, PubMed, Ovid Medline, Scopus and ClinicalTrials.gov with several relevant combinations of keywords, looking for texts or abstracts without any date or language limitations, but using only English keywords. The existing literature only consisted of case reports and series; therefore any paper including one or several cases of PT presenting during pregnancy or breastfeeding was recognized as eligible. Articles with vague description of the tumor which made the diagnosis uncertain, and those lacking data about the tumor and management data were excluded. We contacted authors for more details in cases with incomplete information.

Results: After excluding those with very deficient data, we included 37 studies, counting 43 cases. The mean age of the patients was 31 years (21-43 years). Some features were different from usual PT: bilaterality (16.2%), large size (14.2 ± 8.6 cm), rapid enlargement (79.5%), and rate of malignancy (60.5%).

Conclusion: Our findings show high rates of bilaterality, large size, rapid growth, and malignant pathology in the reported gestational PTs.

Keywords: Breast neoplasms, Hormones, Lactation, Phyllodes tumor, Pregnancy

Cite this article as: Alipour S, Eskandari A, Johar FM, Furuya S. Phyllodes tumor of the breast during pregnancy and lactation; a systematic review. Arch Iran Med. 2020;23(7):488–497. doi: 10.34172/aim.2020.46.

Introduction
In 1838, Johannes Muller for the first time described a benign breast mass which had been dormant for a long period and had then enlarged rapidly. He named it Cystosarcoma Phyllodes based on its leaf-like macroscopic appearance, using the Greek word for leaf, phyllon. However, various nomenclatures have been used for this entity, including fibrosarcoma, fibromatosum, fibrocystadenoma intracanalicular, giant intracanalicular myxoma of the breast, and many other names.1,2 Phyllodes tumor (PT) is the term applied by WHO in classification of tumors, and is the most widely accepted designation.3 The incidence of PT is only 2.1 per million, constituting less than 1% of breast tumors.4 PT is subdivided into three categories based on microscopic features: benign, borderline and malignant.1 Clinically, benign PT looks like fibroadenomas,6 but recurrence after excision of the tumor is much more frequent. Malignant PT, a very uncommon tumor, can be very aggressive with local recurrences and distant metastases.7

PT usually presents as a single, rapidly enlarging, firm, mobile, painless mass with circumscribed margins that may grow out of a previously quiescent small mass. The average size of tumors at detection is about 4-5 centimeters,4 but they can be giant tumors much larger than 10 cm in 20% of cases.7

Hormonal changes during gestation affect breasts significantly, bringing about problems in identifying newly formed masses, or affecting the clinical course of existing tumors. Masses may be erroneously recognized as benign changes, and some diagnostic work up may also be postponed in fear of fetal complications, leading to delayed diagnosis and treatment.10,11 Because of the rarity of this lesion, the influence of pregnancy on the course of PT has not been documented. Also, clinical features, rate of malignancy, treatment and prognosis of the tumor have not been discussed in the literature except for solitary case reports. In order to understand the presentation and course of the disease, we carried out a systematic review to gather all reported cases of PT occurring in pregnancy.
or breastfeeding and find out any specific or common characteristic.

**Materials and Methods**

**Inclusion Criteria**

Any paper including one or several cases of PT presenting during pregnancy, following labor, or during breastfeeding, written in any language, was included. No date limit was considered.

**Exclusion Criteria**

Exclusion criteria consisted of studies where the histology of the tumor was unclear, or the information about tumor characteristics and management of the disease was missing.

**Information Sources**

Explored databases and citation indexes consisted of Google Scholar, PubMed, Scopus, Ovid Medline, and ClinicalTrials.gov.

**Search Strategy and Study Selection**

We designed a structured protocol (Figure 1) and operated accordingly throughout all steps. A comprehensive search of the literature was accomplished, looking for texts or abstracts without any date restriction or language limitations, but using only English keywords. The combinations we used were: ((breast>Title/Abstract)) AND (phyllodes OR phylloides) AND pregnan*[Title/Abstract] in the first round. We repeated the search cycle with other combinations, replacing pregnan* with gestation*, lactat*, and breastfeed*, and (phyllodes OR phylloides) with cystosarcoma, myxoma, intracanalicular fibrocystadenoma, and fibrosarcoma in separate rounds. Our search in Google Scholar continued until we found irrelevant results in 10 subsequent pages. For other databases including PubMed, Scopus, Ovid Medline, and ClinicalTrials.gov, we explored all the results returned. The non-English, non-French titles were provisionally translated to English using Google translate to assess their relevance.

In the next step, titles and abstracts of all obtained studies were screened, and irrelevant works or duplicates were disqualified. Then, the available English and French fulltexts of potentially relevant articles were reviewed by two authors together, discussing problematic cases; and unquestionable papers were included. Thereafter, the challenging articles were approached. In those which consisted of case series of PTs or of breast lumps diagnosed during pregnancy, and contained a case of PT in pregnancy which had not been fully described, our policy was to contact authors and ask them to provide the required items. Also, in case reports with deficient data, we attempted to get in touch with authors to complete data. In the next stage, we browsed the references of the included papers for

![Figure 1. Flowchart of Search Protocol and Study Inclusion.](image-url)
any study or report not retrieved through our search, and treated the detected literature as above.

Data Extraction
Data were extracted systematically from eligible papers by two reviewers using a data-extraction form containing all data items (Figure 2). Study features that were recorded in the form comprised first author name, publication year, article title, journal title, and type of study. Data items concerning patients and tumors consisted of age, gestational age/post-partum, lactating status, past breast history, past medical/surgical history, time of onset from first notification, laterality, largest diameter, rapid growth, tenderness, consistency, skin ulcer, skin erythema, axillary lymphadenopathy, other presentation, modes of imaging, ultrasonography findings, mammographic findings, MRI findings, type of breast surgery, type of axillary surgery, chemotherapy, radiotherapy, other treatment, pathology, histology details, follow-up interval from treatment to last visit, patient condition in last visit, and recurrence/metastasis conditions. Definitions of items are shown in Figure 2.

For bilateral cases, two forms were filled out (while omitting study features in the second form). Data were then entered in a Microsoft excel database designed specifically for this study.

Results
Search Results
By means of numerous keywords and a sensitive search strategy, we were able to find several case reports, plus reports extracted from the case series. Figure 1 shows the number of articles retrieved in various stages of the search. Date of publication of the earliest and latest relevant articles were 195412,13 and 2018,14,15 respectively. Three articles were in languages other than English and French, consisting of Spanish,16 Polish,17 and Portuguese.18 The first two16,17 had English abstracts which were used for data extraction. The other one18 was translated to English via three online translator software including Google translate (https://translate.google.com), Yandex translate (https://translate.yandex.com/translator), and SYSTRAN (http://www.systransoft.com/lp) in order to obtain a more accurate translation and data.

There were six case series which included one PT in pregnancy each, three of which contained enough data and were included.12,13,19 The three others contained very limited data about the case.20-22 We tried to contact the authors in order to obtain more details and succeeded in one case; but they did not have access to data.20 We could not reach the authors of the other two articles21,22; therefore, these three studies were excluded.

Data Extraction Results
Overall, 37 patients with gestational PT were found in this intensive review of the existing literature. Six of them had bilateral tumors; so, 43 gestational phyllodes are discussed here.

Data were missing in some papers. We made several attempts to contact all corresponding authors and even other authors, except for very old papers, for more details. We were successful in eight cases and completed data correspondingly.

The patients’ age and gestational age at time of seeking medical attention, time from onset, past medical histories and family history of cancer, as well as side of tumor and the pathologic type related to malignancy of all included cases are demonstrated in Table 1. All tumors had first presented as a breast lump, except in three patients,11,18,32 one bilateral and benign,18 one malignant,32 and one benign.11 The first clinical picture in these three was breast enlargement. Table 2 shows clinical characteristics of all benign, borderline and malignant tumors in distinct groups.

Results
Search Results
By means of numerous keywords and a sensitive search strategy, we were able to find several case reports, plus reports extracted from the case series. Figure 1 shows the number of articles retrieved in various stages of the search. Date of publication of the earliest and latest relevant articles were 195412,13 and 2018,14,15 respectively. Three articles were in languages other than English and French, consisting of Spanish,16 Polish,17 and Portuguese.18 The first two16,17 had English abstracts which were used for data extraction. The other one18 was translated to English via three online translator software including Google translate (https://translate.google.com), Yandex translate (https://translate.yandex.com/translator), and SYSTRAN (http://www.systransoft.com/lp) in order to obtain a more accurate translation and data.

There were six case series which included one PT in pregnancy each, three of which contained enough data and were included.12,13,19 The three others contained very limited data about the case.20-22 We tried to contact the authors in order to obtain more details and succeeded in one case; but they did not have access to data.20 We could not reach the authors of the other two articles21,22; therefore, these three studies were excluded.

Data Extraction Results
Overall, 37 patients with gestational PT were found in this intensive review of the existing literature. Six of them had bilateral tumors; so, 43 gestational phyllodes are discussed here.

Data were missing in some papers. We made several attempts to contact all corresponding authors and even other authors, except for very old papers, for more details. We were successful in eight cases and completed data correspondingly.

The patients’ age and gestational age at time of seeking medical attention, time from onset, past medical histories and family history of cancer, as well as side of tumor and the pathologic type related to malignancy of all included cases are demonstrated in Table 1. All tumors had first presented as a breast lump, except in three patients,11,18,32 one bilateral and benign,18 one malignant,32 and one benign.11 The first clinical picture in these three was breast enlargement. Table 2 shows clinical characteristics of all benign, borderline and malignant tumors in distinct groups.
Table 1. General Characteristics of All Patients and Tumors

| First Author, Year | Age | Gestational Age | Onset | FH | Side | Type |
|--------------------|-----|----------------|-------|----|------|------|
| Andreola 2012     | 29  | T2             | 6 m   |    | L    | Bor  |
| Aranda 2005       | 32  | T2             | 1 y   |    | R    | Ben  |
| Ariel 1961        | 31  | PP             | —     |    | Y    | Ben  |
| Ball 2012         | 32  | PP             | > 1 y |    | L    | Mal  |
| Blaker 2010       | 27  | T1             | —     |    | R    | Mal  |
| Chai 2017         | 30  | PP             | —     |    | L    | Ben  |
| De Carvalho 1999  | 28  | T2             | 4 m   |    | Y    | Ben  |
| Futsuya 2012      | 32  | T2             | 3 m   |    | R    | Ben  |
| Gentile 2016      | 22  | T2             | 8 w   |    | R    | Bor  |
| Hemant 2017       | 35  | T2             | 6 m   |    | L    | Mal  |
| Kallam 2017       | 32  | T3             | 8 m   |    | L    | Ben  |
| Kelten 2016       | 37  | PP             | —     |    | Y    | L    |
| Lee 2018          | 21  | PP             | 2 m   |    | Y    | Mal  |
| Lester 1954       | 26  | T1             | 1 w   |    | R    | Mal  |
| Li 2008           | 27  | T1             | 1 y   |    | R    | Mal  |
| Likhitmasku 2014  | 36  | T3             | 6 m   |    | N    | Ben  |
| Mard 2000         | 32  | —              | —     |    | L    | Mal  |
| Murthy 2016       | 25  | PP             | —     |    | L    | Ben  |
| Narla 2018        | 28  | PP             | —     |    | L    | Mal  |
| Nejc 2007         | 28  | T3             | 2 m   |    | L    | Mal  |
| Pacchiarotti 2011  | 41  | T2             | 7 m   |    | —    | —    |
| Pandit 1985       | 32  | PP             | 4 m   |    | L    | Mal  |
| Pasta 2012        | 43  | T2             | 1 y   |    | R    | Mal  |
| Pytel 2009        | 25  | T2             | 2 y   |    | L    | Mal  |
| Ray 2011          | 24  | T3             | 9 m   |    | N    | Mal  |
| Reich 1958        | 23  | T1             | 6 y   |    | L    | Mal  |
| Sharma 2004       | 35  | T3             | 3 y   |    | L    | Ben  |
| Simpson 2007      | 29  | T1             | 7 m   |    | N    | Mal  |
| Testori 2015      | 33  | 4vPP           | 4 y   |    | N    | Mal  |
| Tortoriello 2017  | 37  | T1             | 9 m   |    | N    | Mal  |
| Vergine 2012      | 27  | PP             | a few m |  | R    | Mal  |
| Vintea 2016       | 29  | T2             | 2 m   |    | L    | Ben  |
| Ward 1986         | 28  | —              | A few m |  | —    | —    |
| Way 1998          | 35  | T3             | 3 w   |    | R    | Mal  |
| Weledji 2014      | 30  | PP             | 11 m  |    | R    | Bor  |
| White 1954        | 22  | T1             | —     |    | —    | Mal  |

Ben, benign; Bor, borderline; FH, family history of breast cancer; L, left; LB, left breast; Mal, malignant; m, months; N, No; PP, post-partum period; PT, phyllodes tumor; R, right; RB, right breast; T, trimester of pregnancy; T1, 1–12 week; T2, 13–27 weeks; T3, 28–40 weeks; w, weeks; Y, yes; y, years.

Ultrasonographic scan was not performed in many cases, namely those related to past times, and thus related features were mentioned in only 23 tumors. Most tumors were circumscribed, and either heteroechoic or hypoechoic, with a predilection for the latter. Of the 15 cases which had described lobulations of the mass on ultrasound, 12 had lobulations, whereas 3 did not; one in each category of benign, borderline, and malignant tumor. Among those explained, margins were irregular in two malignant and one borderline PT, and regular in 10 others. Vascularity as assessed by Doppler ultrasonographic scan was detected in seven cases, namely in three benign and four malignant cases.

Management and follow-up of benign, borderline and malignant tumors are shown in Table 3.

The authors of the included papers defined the size of lesions with varying terms. Some reported measured dimensions of tumors, some described largeness of PTs,
### Table 2. Clinical Presentation of All Tumors

| First Author | Rapid Growth in Pregnancy/Lactation | Largest Diameter (cm) or Mass/Breast Size | Clinical Presentation | Tumor Histology |
|--------------|------------------------------------|------------------------------------------|----------------------|----------------|
| Aranda       | Y                                  | 23, WB                                   | N, Soft, N, Y, N     | Benign         |
| Cha          | Y                                  | Huge                                     | N, Hard, N, Y, N     |               |
| Chair        | Y                                  | 20                                       | N, mixb, N, N, N     |               |
| DeCarvalho   | Y                                  | WB                                       | N, - , Y, Y, N       |               |
| Kallam       | Y                                  | 20, WB                                   | N, mixc, N, Y, N     |               |
| Likhitmasku  | Y                                  | 20 ,WB                                   | Y, Firm, Y, Y        |               |
| Mtei         | R                                  | N                                        | 10, Firm, N, N, N    |               |
| Murthy       | Y                                  | >Half breast                             | Y, - , N, N, N       |               |
| Sharma       | Y                                  | 20                                       | - , - , Y, N, N      |               |
| Vintea       | Y                                  | 7.6c                                     | N, Hard, N, Y        |               |
| Way          | Y                                  | 5                                        | N, Firm, N, N, N     |               |
| Andreola     | L                                  | WB                                       | - , Hard, N, N, N    | Borderline     |
| Furuya       | Y                                  | 5                                        | N, Soft, N, N, N     |               |
| Gentile      | Y                                  | 19                                       | Y, - , Y, Y, N       |               |
| Welledji     | Y                                  | 10c                                      | N, Firm, N, N, N     |               |
| Ariel        | -                                  | 4                                        | Y, Firm, N, N, N     |               |
| Bal          | Y                                  | WB                                       | Y, hard, N, Y, Y     |               |
| Blake        | N                                  | -                                        | N, - , N, N, N, N    |               |
| Hernanz      | L                                  | -                                        | Half breast, N, - , N| Malignant      |
| Kelten       | Y                                  | 13e                                      | Y, - , N, Y, N       |               |
| Lee          | N                                  | -                                        | N, Firm, N, N, N     |               |
| Lester       | N                                  | 4                                        | N, - , N, N, N       |               |
| Li           | Y                                  | Huge                                     | Y, - , Y, Y, N       |               |
| Mtei         | L                                  | 15, WB                                   | N, - , N, N, N       |               |
| Narla        | Y                                  | 14f                                      | N, Firm, N, N, N     |               |
| Nejc         | Y                                  | 15                                       | N, Firm, N, N, N     |               |
| Pacchiarotti  | Y                                  | 6b                                       | N, Firm, N, N, N     |               |
| Pandit       | L                                  | 6f                                       | N, - , Y, Y, N       |               |
| Pasta        | R                                  | N                                        | 2.5e, N, - , N, N, N |               |
| Pytel        | Y                                  | -                                        | N, - , N, N, N       |               |
| Ray          | Y                                  | 22                                       | Y, Mixb, N, N, N     |               |
| Reich        | L                                  | 14                                       | N, - , N, N, N       |               |
| Simpson      | Y                                  | 17f                                      | N, - , N, N, Y       |               |
| Testori       | Y                                  | 40, WB                                   | N, - , N, Y, Y       |               |
| Tortoriello   | Y                                  | 24                                       | N, - , N, N, N       |               |
| Vergine      | Y                                  | 10                                       | - , - , N, N, N      |               |
| Ward         | -                                  | 6.5                                      | - , - , - , - , -    |               |
| White        | -                                  | 12                                       | - , - , - , - , -    |               |

L, left; N, No; R, right; UOQ, upper outer quadrant; WB, whole breast; Y, yes.

* Multiple masses from 3 to 10 cm.  † Heterogeneous consistency.  ‡ Two masses at time of excision, 7 cm and 18 cm.  § Confluent masses.  ¶ Size not mentioned in clinic, but in gross histology.  * Multiple nodules form 3–6 cm in left breast in histologic exam.
### Table 3. Treatment and Follow up of All Tumors

| Author         | Side | Surgery                                   | Time and Result of Follow up                          | Histology |
|----------------|------|-------------------------------------------|------------------------------------------------------|-----------|
| Aranda         | R    | Mastectomy                                |                                                      | Benign    |
| Cha            | L    | Lumpectomy                                |                                                      |           |
| Cha            | L    | Mastectomy+ reconstruction                | 10 m, good                                           |           |
| De Carvalho    | L R  | Bilateral mastectomy                      | 2 m, good                                            |           |
| Kallam         | L    | Mastectomy                                | Until now (3 y): good                                |           |
| Likhitmasku    | L    | Mastectomy+ axillary dissection+ reconstruction | Until now (6 y): good                                |           |
| Mrad           | R    | Wide lumpectomy                           | 17 m: good                                           |           |
| Murthy         | L    | Wide lumpectomy                           | 3 y: good                                            |           |
| Sharma         | L    | Mastectomy                                |                                                      |           |
| Vintea         | L    | Wide lumpectomy                           | 6 m: good                                            |           |
| Way            | R    | First: lumpectomy, margin positive; then wide lumpectomy, margin negative | 1 y: normal pregnancy 2.5 y: good                       |           |
| Andreola       | L R  | L: mastectomy; R: lumpectomy              |                                                      |           |
| Furuya         | R    | Mastectomy+ axillary sampling*            | Until now (? y): good                                |           |
| Gentile        | R    | Mastectomy+ reconstruction                |                                                      |           |
| Weledji        | R    | First: wide lumpectomy; then: mastectomy for recurrence | 4 m: local recurrence; until now*: good               |           |
| Ariel          | R    | Radical mastectomy                        | 6 m: 11th thoracic vertebra metastasis                |           |
| Bal            | L    | Subcutaneous mastectomy+ axillary sampling+ reconstruction | 6 m: good                                               |           |
| Blaker         | R    | First: lumpectomy; margins positive; Then: margin re-excision; margins negative | 8 m: good                                               |           |
| Hernanz        | R    | RB: subcutaneous mastectomy+ reconstruction; LB: First lumpectomy; then subcutaneous mastectomy for potential residue+ reconstruction |                                                      |           |
| Kelten         | L    | Mastectomy                                |                                                      | Malignant |
| Lee            | R    | Lumpectomy                                |                                                      |           |
| Lester         | —    | First: lumpectomy; at 6m: radical mastectomy+ axillary dissection for recurrence | 6 m of lumpectomy: Local recurrence; 2 y: widespread metastases, death |           |
| Li             | R    | First: mastectomy; then: excision and flap for recurrence in chest wall |                                                      |           |
| Mrad           | L    | Mastectomy                                | Good                                                 |           |
| Narla          | L    | First: wide lumpectomy; then mastectomy due to residue |                                                      |           |
| Nejc           | L    | First: lumpectomy; then margin re-excision for mastectomy | 20 m: free of disease                                |           |
| Pacchiarotti   |      | First excisional biopsy; then quadrantectomy for Mal |                                                      |           |
| Pandit         | L R  | LB: mastectomy; RB: lumpectomy            |                                                      |           |
| Pasta          | R    | First: lumpectomy; then: wide lumpectomy for Mal and close margins | 1 y: good                                               |           |
| Pytel          | L    | Mastectomy after 2 y                      |                                                      |           |
| Ray            | R    | At 2 m PP: mastectomy                     |                                                      |           |
| Reich          | L    | First: lumpectomy; at recurrence: radical mastectomy | 14 y of first surgery: death from extensive recurrence* |           |
| Simpson        | R    | First radical mastectomy+ axillary sampling; ChT in early PP+ RT |                                                      |           |
| Testori        | R    | Radical mastectomy+ axillary dissection   | 18 m: good                                           |           |
| Tortoriello    | L    | Lumpectomy with sufficient margin         | Until now (2.5 y): good                               |           |
| Vergine        | R    | Wide lumpectomy; then mastectomy for histology results+ RT | 1 y: good                                               |           |
| White          | —    | 2 m gestation: lumpectomy; 3 m gestation: mastectomy | 3 y: healthy pregnancy and delivery; 8 y: local recurrence; 11 y: good |           |

ChT, chemotherapy; L, left; LB, left breast; Mal, malignant; m, month; PP, post-partum; R, right; RB, right breast; RT, radiotherapy; w, week; y, year.

*Asked and answered by mail, not in article. †Surgery postponed because of second Py, then, rapid growth to 15 cm in 3 m, then surgery performed. ‡Defined as compartmental mastectomy in article.

ChT, chemotherapy; L, left; LB, left breast; Mal, malignant; m, month; PP, post-partum; R, right; RB, right breast; RT, radiotherapy; w, week; y, year.

*Asked and answered by mail, not in article. †Surgery postponed because of second Py, then, rapid growth to 15 cm in 3 m, then surgery performed. ‡Defined as compartmental mastectomy in article.
and some others outlined the amount of breast tissue involved by the mass. Clinical size as measured was missing in 13 tumors. The mean size of tumors was 14.2 ± 8.6 cm in the rest. However, we intended to enter most included studies in size scrutiny in order to obtain an estimation of the relation of tumor size to pathologic type. We therefore attempted to combine and unify size definitions, and then classify PTs accordingly. Bearing in mind the range of dimensions and terms used in included studies, the average size of non-gestational PT which is around 4–5 cm, and T staging of breast cancer according to the TNM classification, we defined the following scale: small < 5 cm; 5 cm ≤ medium < 10 cm; 10 cm ≤ large < 15 cm; huge ≥ 15 cm. We could not assign numbers to non-numeric designations; so, we allocated descriptive terms of our self-defined scale to all PTs with any type of size definition. We considered PTs involving half the breast as large and the whole breast as huge. Table 4 illustrates these results as well as main numeric values after excluding missing data, based on pathologic type of tumors.

Skin signs including color changes and ulcerative lesions were mentioned in some case reports, and some studies included images which clearly showed changes in the skin. We considered these characteristics as absent where they were not mentioned or pictured, because clinical findings were defined. All these skin findings are shown in Table 5 in relation to pathologic type of PT.

Discussion

We performed a systematic review of the literature and collected 43 suitable cases of PT occurring in pregnancy. Previous review articles on this subject consisted of 7 patients (one bilateral: 8 tumors), 9 patients (one bilateral: 10 tumors), and 14 patients (one bilateral: 16 tumors). The mean age of patients in this study was 31 years (21–43 years), younger than the average of 40–45 years for usual PT; this difference is ordinary because gestational tumors are studied. The youngest patient was 21 and the oldest 43 years old.

The most common presentation of PT is a breast lump, which used to be self-detected previously, and is frequently being detected in imaging recently. This fact also applies to this study, where 90.7% of tumors presented as a mass; and the 9.3% which presented with breast enlargement showed a mass later on.

Due to massive alterations in hormonal milieu such as the 100-fold and 1000-fold increments in serum estrogen and progesterone, respectively, breasts undergo substantial physiologic changes during pregnancy. Vascular hyperplasia and proliferation of alveoli and lobules cause higher breast volume, weight, firmness, and density; sometimes twice that of the usual breast. There are two consequences to these: detection of breast lesions becomes difficult both on examination and imaging, and some existing diseases take an altered course, such as hastened enlargement of hormonally responsive lumps. It has generally been said that most gestational breast lumps have indeed occurred before pregnancy but are detected as an expanding or new mass at this time in reaction to hormonal alterations. Evidence has not proved that PT is under the influence of steroid hormones, but this theory has been put forward due to reports of rapid enlargement in gravid women. The reports were not uniform for definition of size of lesions. However, according to our suggested classification (Table 4), most lesions were large or huge. This can be due to the higher probability of large lesions to be detected or reported. Nonetheless, data in Table 4 clarify that size had no relation with pathologic type in these gestational PTs.

In this study, out of 39 tumors which were clinically described, 31 (79.5%) had undergone rapid enlargement during pregnancy or lactation. This represents a high incidence, which highlights the probable dependence of PT on sex hormones. Also, fast growth was seen in 92%, 60%, and 82% of benign, borderline, and malignant tumors, respectively; so, this feature alone might not be much alarming as a signal of malignant behavior during pregnancy or breastfeeding.

No predilection for the right or left breast is expected in PT. Consistently, 20 tumors were in the left and 20 in the right breast in this study; the side of the tumor was not mentioned in three reports. Bilaterality is a rare event in PT, reported in 0.3–3.5% of cases. In our study, 16.2% of patients (6 out of 37) had bilateral disease: five synchronous and one metachronous. This higher

Table 4. Size of All Phyllodes Tumors According to Pathologic Type

| Type     | Mean | Min | Max | Missing | Small (%) | Medium (%) | Large (%) | Huge (%) | Missing |
|----------|------|-----|-----|---------|-----------|------------|-----------|----------|---------|
| Benign   | 15.6 | 5   | 23  | 4       | 0 (0%)    | 2 (16.5%)  | 1 (8.5%)  | 9 (75%)  | —       |
| Borderline| 9.5  | 5   | 19  | 2       | 0 (0%)    | 1 (25%)    | 1 (25%)   | 2 (50%)  | 1       |
| Malignant| 13.1 | 1.5 | 40  | 7       | 4 (18%)   | 3 (13%)    | 6 (27%)   | 9 (41%)  | 4       |
| All      | 14.2 | 1.5 | 40  | 13      | 4 (10%)   | 7 (18%)    | 9 (23%)   | 19 (49%) | 4       |

Table 5. Breast Skin Changes of All Tumors Based on Pathologic Type

| Type (Total) | Skin Ulcer | Skin Discoloration | Skin Changes\(a\) |
|--------------|------------|--------------------|-------------------|
| Benign (12)  | 4 (58%)    | 5 (56%)            | 7 (58%)           |
| Borderline (5)| 1 (14%)    | 0 (0%)             | 1 (8%)            |
| Malignant (26)| 2 (28%)    | 4 (44%)            | 4 (33%)           |
| Total        | 7 (100%)   | 9 (100%)           | 12 (100%)         |

\(a\) Skin ulcer and/or discoloration.
frequency might be incidental, but could also emphasize hormone-responsiveness of PT.

Normally, benign PT is much more frequent than the malignant form. On the other hand, most breast disorders presenting during pregnancy are benign.

Our study shows a higher frequency for malignant tumors compared to benign ones. Malignant PTs accounted for 26 cases (60.46% of all tumors); among them, three patients had bilateral malignant tumors, while one had a benign PT on one side and a malignant on the other. There were 12 benign tumors (27.90%) including one bilateral, and there were 5 borderline PTs (11.62%), also with one bilateral case. The small number of cases precludes any analysis and conclusion, but this predilection for malignancy cannot be attributed to higher detection rates of malignant disease due to larger size or precipitated growth, because these features were sufficiently frequent in the benign tumors in our study, as well. We hypothesize that female sex hormones might induce malignant transformation in benign PT. Two of the patients affected by malignant PT had become pregnant via hormonal stimulation because of infertility. While this might just be an incidental finding, it may also imply a considerable frequency of high-level hormone exposure, and may be in favor of the above hypothesis.

The onset of disease varied widely among patients in this study, from one week to 6 years, with a mean of 12.8 months. The post-partum period, and then the second trimester of pregnancy were the most common times of presentation. Unexpectedly, onset was shorter for benign tumors, with an average of about 10 months; and longer for malignancies, with an average of around 14 months. We have no explanation for this finding, except that this might imply that malignant cases had long been benign tumors and had undergone malignant transformation through gestational changes, which might be thus in favor of the hypothesis about malignant transformation of benign PT under influence of sex hormones. Here again, the rarity of cases prevents conclusion.

Phyllodes lumps are generally painless. In our study, pain or tenderness was reported in 9 out of 40 PTs; including 2 (17%), 1 (20%) and 6 (26%) benign, borderline and malignant tumors, respectively. This probably illustrates pregnancy-induced mastalgia or associated puerceral mastitis and cannot be determined as a specific feature of gestational PT.

Because of its size and lobulation, PT can lead to stretching and thinning of the overlying skin; ulcers may follow in neglected cases. This can occur in any type of PT regardless of its malignant or benign nature. Skin findings were not more common in malignancy in our study. These appeared in 63%, 20%, and 15% of benign, borderline and malignant cases, respectively. The distribution of skin findings according to type of tumor is shown in Table 5.

Treatment of PT consists of wide local excision of the tumor to clear margins, without axillary surgery. A margin of 1 cm has been traditionally accepted, and wider resections are recommended for borderline and especially malignant PT. Mastectomy is performed in large tumors, most commonly for borderline and malignant PT, and in recurrent tumors. It is worth noting that newer evidence drives toward thinner margins.

In our study, mastectomy was the method of surgery in benign PT for 7 tumors (58.3% of benign tumors), and lumpectomy in 5 (41.7%) of them, including wide margins in 4. We are aware of the follow-up of 6 patients, for an average of 27 months, and a maximum of 6 years. All of them were fine and no recurrence had been detected.

For borderline PT, lumpectomy had been carried out in two and mastectomy in three cases. Recurrence of one of the lumpectomies had been subsequently managed by mastectomy. We also know about the follow-up of that one case, which had no recurrence after more than 5 years.

For malignant PT, 19 mastectomies and 18 lumpectomies had been performed, the latter consisting of quadrantectomy in one and wide excision in two cases. Length of follow-up is known for 13 tumors, and was 65 months on average, with a maximum of 22 years. Local recurrence occurred in three patients at 6 months, 19 2 years, and 3 years after treatment. Distant metastases occurred in three patients at 6 months, 2.5 years (2 years after local recurrence), and 14 years after treatment of the primary tumor. These consisted of solitary bone lesion, widespread metastasis, and both regional and extensive distant metastases, respectively; the latter two resulted in the patient’s death. The small number of followed patients and the diversity in extent of tumor and surgery preclude analysis of the association of method of surgery with prognosis. Nevertheless, as would be expected, and supported by these limited data, the course of the disease and prognosis were noticeably worse in malignant cases versus borderline and benign PT.

The effect of systemic endocrine therapy or chemotherapy, as well as radiotherapy, has not been completely defined in the management of PT. In our study, one patient with malignant PT had undergone both chemotherapy and radiotherapy, and another had received radiation after the operation.

This study had some limitations. We could not contact some authors of published articles which included one case of PT among other cases, and these were excluded. The high rate of malignancy in these gestational PTs could be the result of publication bias, since malignant PT, given their rarity, may be more likely than benign cases to be published as case reports. Furthermore, the sample size precluded formal statistical tests of the hypotheses. We suggest further research on the subject with a large-scale work gathering all PTs reported in the literature, to compare the proportion of malignant PTs in pregnant versus non-pregnant patients.
In conclusion, bilaterality, large size, and rapid growth were more frequent than expected in the reported gestational PTs. However, the size of the tumor and the speed of growth were not associated with higher rates of malignancy in these patients. Because of the high rates of malignancy in gestational PT, and occurrence of two cases of malignant PT following hormonal stimulation for pregnancy in infertile patients, we hypothesize that female sex hormones might induce malignant transformation of benign PT, and propose further research as well as in vitro and in vivo verification of this idea.

Authors’ Contribution
SA conceptualized, designed and managed the study; gathered data, wrote the manuscript. AE collaborated in design and data gathering and processing; collaborated in quality control, edited and critically reviewed, and approved the manuscript. FMJ and SF collaborated in collection of data, collaborated in quality control, and approved the manuscript.

Conflict of Interest Disclosures
The authors have no conflict of interest.

Ethical Statement
The study was supported by Tehran University of Medical Sciences (Grant No: 24994).

Acknowledgements
We would like to acknowledge Dr. Akram Seifollahi for her consultation on histologies described in case reports, and Drs Anji Reddy Kallam, Elroy Blaker KM, Sahoo S, Schweichler MR, Chagpar AB. Malignant phyllodes tumors in pregnancy. Am Surg. 2010;76(3):302-5.

Vintea A, Sima R, Burcoț T, Bânceanu G, Toader O. The management of a rare breast tumor in pregnancy. J Surg Sci. 2016;3(4):187-91.

Lester J, Stout AP. Cystosarcoma phylloides. Cancer. 1954; 7(2):335-53. doi: 10.1002/1097-0142(195403)7:2<335::AID-CNCR2820070219>3.0.CO;2-J

White TT. Carcinoma of the breast and pregnancy: analysis of 920 cases collected from the literature and 22 new cases. Ann Surg. 1954;139(1):9. doi: 10.1097/00000658-195403000-00003.

Elroy Blaker, Patrick Weledji, Emilia Caputo, Raffaele Tortoriello, Romina Sima, Harper AS, Sima R, Blaker KM, Sahoo S. Malignant phyllodes tumors in pregnancy. Am J Obstet Gynecol. 2019;221(1):e1-e6. doi: 10.1016/j.ajog.2019.01.077.

Narla SL, Stephen P, Kurian A, Annapurneswari S. Well-differentiated liposarcoma of the breast arising in a background of malignant phyllodes tumor in a pregnant woman: A rare case report and review of literature. Indian J Pathol Microbiol. 2018;61(4):577-9. doi:10.4103/IJPM.IJPM_238_17.

Lee MV, Shaw HL, Chi T, Brazeal HA, Holley SO, Appleton CM. Palpable breast abnormalities in women under age 40. Breast J. 2018;24(5):798-805. doi: 10.1111/tbj.13035.

Aranda C, Sotelo M, Torres A, Zárate M. Phyllodes tumor and pregnancy. A report of a case. Ginecología y obstetricia de Mexico. 2005;73(10):378-392.

Pytel J, Dedeucjs M, Naze M, Strózyk G, Brzezinski J. Malignant breast phyllodes tumor in pregnancy-a case report. Prz Menopauzalny. 2009;13(6):331.

diagnosis of malignant phyllodes tumors. Am J Surg. 1993;165(3):376-79. doi: 10.1016/S0002-9610(93)90200-7.

Ward RM, Evans HL. Cystosarcoma phylloides. A clinicopathologic study of 26 cases. Cancer. 1986;58(10):2282-9. doi: 10.1002/1097-0142(19861115)58:10<2282::AID-CNCR2820581021>3.0.CO;2-2.

Damrich D, Glasser G, Dolan M. The characteristics and evaluation of women presenting with a breast mass during pregnancy. Primary Care Update ob/gyns. 1998;5(1):21-3. doi: 10.4103/IJPM.IJPM_238_17.

Haq SM. Breast Lumps Presenting During Pregnancy. J Rawalpindi Med Coll. 2012;16(1):42-4.

Abdelkrim SB, Trabelsi A, Bouzrara M, Boudagga MZ, Memmi A, Bakir DA, et al. Phyllodes tumors of the breast: a review of 26 cases. World J Oncol. 2010;1(3):129. doi: 10.4021/wjo2010.06.220w.

Andreea J, Damin A, Andreela C, Cristea I, Varella M, Canal L, et al. Giant borderline phyllodes breast tumor in pregnancy. J Sonologic Int Soc. 2012;1(3).

Lester J, Stout AP. Cystosarcoma phylloides. Cancer. 1954; 7(2):335-53. doi: 10.1002/1097-0142(195403)7:2<335::AID-CNCR2820070219>3.0.CO;2-J

White TT. Carcinoma of the breast and pregnancy: analysis of 920 cases collected from the literature and 22 new cases. Ann Surg. 1954;139(1):9. doi: 10.1097/00000658-195403000-00003.

Furuya S, Miura K, Aikawa T, Nakagomi H, Mri M, Oyama T. A case of cystosarcoma phyllodes mammae of johannes section. J Plast Surg. 2015;48(1):81. doi: 10.4103/0970-0358.155276.
case of phyllodes tumor of the breast grown rapidly during the last period of pregnancy. J JPN Surg Assoc. 2012;73(4):780-5. doi: 10.3919/jjsa.73.780.

29. Gentile LF, Gaillard WF, Wallace JA, Spigelur LR, Alizadeh L, Lentz A, et al. A Case of a Giant Borderline Phyllodes Tumor Early in Pregnancy Treated with Mastectomy and Immediate Breast Reconstruction. Breast J. 2016;22(6):683-7. doi: 10.1111/tbj.12663.

30. Hernanz F, González-Noriega M, Arozamena B, Solano J, García J. Bilateral synchronous breast malignant phyllodes in a pregnant woman. Breast J. 2018;24(3):412-3. doi: 10.1111/tbj.12961.

31. Kallam AR, Kanumury V, Korurimilli RM, Gudeli V, Polavarapu H. Massive Benign Phyllodes Tumour of Breast Complicating Pregnancy. J Clinical Diagn Res. 2017;11(3):PD08. doi: 10.7860/JCDR/2017/26277.992.

32. Kelten C, Boyaci C, Leblebici C, Behzatoglu K, Trabulos DC, Sari S, et al. Malignant phyllodes tumors including aneurysmal bone cyst-like areas in pregnancy—a case report and review of the literature. Breast Care. 2016;11(4):291-4. doi: 10.1159/000448236.

33. Li X, Yang Y, Wang J, Ma B, Jin Y, Li R. Surgical treatment of giant recurrent breast phyllodes tumor. J Huazhong Univ Sci. 2008;28(6):688-92. doi: 10.1007/s11596-008-0617-4.

34. Mard K, Driss M, Maelj M, Romdhane KB. Bilateral cystosarcoma phyllodes of the breast: a case report of malignant form with contralateral benign form. Ann Diagn Pathol. 2000;4(6):370-2. doi: 10.1053/adpa.2000.19375.

35. Murthy SS, Raju I, Nair HG. Phyllodes tumor in a lactating breast. Clin Med Insight Pathol. 2016;9:CPath. S38476. doi: 10.4137/CPath.s38476.

36. Nejc D, Pasz-Walczak G, Plekarski J, Pluta P, Bilski A, Sek P, et al. Astonishingly rapid growth of malignant cystosarcoma phyllodes tumor in a pregnant woman—a case report. Int J Gynecol Cancer. 2008;18(4):856-9. doi: 10.1111/j.1525-1438.2007.01077.x.

37. Pacchiariotti A, Selman H, Gentile V, Pacchiariotti A, Milazzo GN, Lanzilotti G, Lolino S, Frati P. First case of transformation of breast fibroadenoma to high-grade malignant phyllodes tumor in an in vitro fertilization patient: misdiagnosis of recurrence. Cancer. 1997;44(4):723-59. doi: 10.1001/archsurg.1942.01210220126009.

38. Pasta V, Monti M, Cialini M, Vergine M, Urciuoli P, Iacovelli A, et al. Primitive sarcoma of the breast: new insight on the proper surgical management. J Exp Clin Canc Res. 2015;34(1):72. doi: 10.1186/s13046-015-0190-1.

39. Hayati F, Lian HH, Azizan N, Ali AA, Abidin ZAZ, Suhaili MA. Approaches to phyllodes tumour of the breast: a review article. Int Surg J. 2017;4(3):841-5. doi: 10.18203/2349-2902.isj20170841.

40. Yu JH, Kim MJ, Cho H, Liu HJ, Han SJ, Ahn TG. Breast diseases during pregnancy and lactation. Obstet Gynecol Sci. 2013;56(3):143-59. doi: 10.5468/ogs.2013.56.3.143.

41. Lee SS, Hartman HJ, Kuzmiak CM, Crosby KL. The management of breast symptoms in the pregnant and lactating patient. Curr Obstet Gynecol Rep. 2013;2(1):53-8. doi: 10.1007/s13669-012-0037-0.

42. Stephenson JR HE, Gross S, Gumport SL, Meyer HW. Cystosarcoma phylloides of the breast: a review of the literature with the addition of 15 new cases. Ann Surg. 1952;136(5):856. doi: 10.1097/00000658-195211000-00009.

43. Guilhot E, Couturaud B, Reynal F, Curnier A, Ravinet J, Léa M, et al. Management of phyllodes breast tumors. Breast J. 2011;17(2):129-37. doi: 10.1111/j.1524-4741.2010.01456.x.

44. Grabowski J, Salzstein SL, Sadler GR, Blair SL. Malignant phyllodes tumors: a review of 752 cases. Am Surg. 2007;73(10):967-9.